Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference

Rhea-AI Summary

Adicet Bio (NASDAQ: ACET), a clinical-stage biotechnology company specializing in allogeneic gamma delta T cell therapies for cancer, announced its participation in the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023. Chen Schor, President and CEO, will be featured in a panel titled "Off-the-Shelf CART – Current Snapshot" at 11:00 a.m. ET. Attendees can arrange one-on-one meetings with the Adicet team through their sales representatives at Canaccord Genuity. Adicet is advancing a pipeline of engineered gamma delta T cells designed for enhanced tumor targeting and effective immune responses against cancer. For more details, visit Adicet Bio's website.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 20, 2023.

Details of the event are as follows:
Panel: “Off-the-Shelf CART – Current Snapshot”
Date: Thursday, April 20, 2023
Time: 11:00 a.m. ET

The Adicet Bio team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Canaccord Genuity to register for a meeting with the company.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005139/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

FAQ

What is the date of Adicet Bio's participation in the Canaccord Genuity Horizons in Oncology Virtual Conference?

Adicet Bio will participate in the conference on April 20, 2023.

What panel will Chen Schor be part of at the conference?

Chen Schor will participate in the panel titled 'Off-the-Shelf CART – Current Snapshot'.

At what time will the panel featuring Adicet Bio take place?

The panel will take place at 11:00 a.m. ET on April 20, 2023.

How can attendees arrange meetings with Adicet Bio during the conference?

Attendees can contact their sales representative at Canaccord Genuity to register for a one-on-one meeting with Adicet Bio.

What therapies is Adicet Bio developing for cancer treatment?

Adicet Bio is developing allogeneic gamma delta T cell therapies designed for effective tumor targeting and immune response.